Intech Investment Management LLC Raises Stock Position in IDEXX Laboratories, Inc. $IDXX

Intech Investment Management LLC boosted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 966.0% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 35,094 shares of the company’s stock after buying an additional 31,802 shares during the period. Intech Investment Management LLC’s holdings in IDEXX Laboratories were worth $23,742,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. EverSource Wealth Advisors LLC lifted its holdings in IDEXX Laboratories by 2.5% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 621 shares of the company’s stock worth $397,000 after purchasing an additional 15 shares in the last quarter. Harbour Investments Inc. lifted its holdings in IDEXX Laboratories by 13.3% in the 4th quarter. Harbour Investments Inc. now owns 136 shares of the company’s stock worth $92,000 after purchasing an additional 16 shares in the last quarter. CWA Asset Management Group LLC lifted its holdings in IDEXX Laboratories by 3.5% in the 4th quarter. CWA Asset Management Group LLC now owns 509 shares of the company’s stock worth $344,000 after purchasing an additional 17 shares in the last quarter. Stratos Wealth Partners LTD. lifted its holdings in IDEXX Laboratories by 1.7% in the 3rd quarter. Stratos Wealth Partners LTD. now owns 1,069 shares of the company’s stock worth $683,000 after purchasing an additional 18 shares in the last quarter. Finally, Cary Street Partners Investment Advisory LLC lifted its holdings in IDEXX Laboratories by 11.5% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 174 shares of the company’s stock worth $111,000 after purchasing an additional 18 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently commented on IDXX shares. Piper Sandler lowered their price target on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a report on Monday, February 9th. Weiss Ratings lowered IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Barclays cut their price objective on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Finally, Citigroup initiated coverage on IDEXX Laboratories in a research report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price objective for the company. Seven investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $751.00.

IDEXX Laboratories Trading Up 3.1%

Shares of IDEXX Laboratories stock opened at $568.03 on Friday. The firm has a market cap of $44.81 billion, a price-to-earnings ratio of 41.83, a PEG ratio of 3.20 and a beta of 1.58. IDEXX Laboratories, Inc. has a twelve month low of $504.56 and a twelve month high of $769.98. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. The business has a 50-day moving average price of $564.85 and a 200-day moving average price of $637.70.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.12 billion. During the same period in the previous year, the firm posted $2.91 earnings per share. The firm’s revenue for the quarter was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Equities research analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

Insider Buying and Selling at IDEXX Laboratories

In other news, EVP Nimrata Hunt sold 1,758 shares of the business’s stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $634.57, for a total transaction of $1,115,574.06. Following the transaction, the executive vice president owned 18,141 shares of the company’s stock, valued at approximately $11,511,734.37. The trade was a 8.83% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.79% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.